Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study of RAY1216 Tablets in Patients With Mild to Moderate SARS-CoV-2 Infection

NCT05620160 is registered in ClinicalTrials.gov with Guangdong Raynovent Biotech Co., Ltd as lead sponsor.

NCT NCT05620160
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05620160 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study of RAY1216 Tablets in Patients With Mild to Moderate SARS-CoV-2 Infection
Lead sponsor
Guangdong Raynovent Biotech Co., Ltd
Phase
Phase 3
Overall status
Completed
Start date
November 12, 2022
Completion date
March 28, 2023
Enrollment
1,359 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mild to moderate covid-19